文献速递造血干细胞移植与细胞治疗白血病

CD28/4-1BB CD123 CAR-T细胞治疗母细胞性浆细胞样树突状细胞肿瘤

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
PubMed 文献 · Leukemia · 2020-02-28

该研究探讨了靶向CD123的CD28/4-1BB CAR-T细胞对母细胞性浆细胞样树突状细胞肿瘤(BPDCN)的免疫功能、抗白血病疗效及安全性。体外实验显示CAR-T细胞可识别CD123抗原并有效杀伤BPDCN细胞系和患者来源的PDX细胞;体内实验表明CAR-T治疗可降低BPDCN原始细胞负荷,且对低表达CD123的正常细胞毒性低,提示脱靶毒性可能较小。

要点

  • CD28/4-1BB CD123 CAR-T细胞可有效杀伤BPDCN细胞系和PDX细胞。
  • 体内治疗可降低BPDCN原始细胞负荷。
  • 对低表达CD123的正常细胞毒性低,提示安全性较好。

核心结论

  • CD28/4-1BB CD123 CAR-T细胞在BPDCN中显示出抗白血病疗效且脱靶毒性低,支持进一步临床评估。

研究设计与样本

  • 研究采用逆转录病毒和慢病毒工程化的CD28/4-1BB CD123 CAR-T细胞,在体外和体内模型(包括BPDCN细胞系、PDX细胞、人源化小鼠)中评估其功能、疗效和安全性。

主要发现

  • CD28/4-1BB CD123 CAR-T细胞通过CD123抗原识别对BPDCN细胞发挥效应功能,并有效杀伤BPDCN细胞系和BPDCN来源的PDX细胞。
  • 体内CD28/4-1BB CD123 CAR-T细胞治疗可促进BPDCN原始细胞负荷下降,显示强疗效。
  • 来自BPDCN患者的T细胞经CD28/4-1BB CD123 CAR转导后,在体外成功消除自体BPDCN原始细胞。
  • 在人源化小鼠模型中,效应CAR-T细胞对低表达CD123的正常细胞亚群细胞毒性低或无毒性,提示潜在的on-target/off-tumor毒性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is associated with a remarkably poor prognosis and with no treatment consensus. The identification of relevant therapeutic targets is challenging. Here, we investigated the immune functions, antileukemia efficacy and safety of CD28/4-1BB CAR T cells targeting CD123 the interleukin (IL)-3 receptor alpha chain which is overexpressed on BPDCN. We demonstrated that both retroviral and lentiviral engineering CD28/4-1BB CD123 CAR T cells exhibit effector functions against BPDCN cells through CD123 antigen recognition and that they efficiently kill BPDCN cell lines and BPDCN-derived PDX cells. In vivo, CD28/4-1BB CD123 CAR T-cell therapy displayed strong efficacy by promoting a decrease of BPDCN blast burden. Furthermore we showed that T cells from BPDCN patient transduced with CD28/4-1BB CD123 CAR successfully eliminate autologous BPDCN blasts in vitro. Finally, we demonstrated in humanized mouse models that these effector CAR T cells exert low or no cytotoxicity against various subsets of normal cells with low CD123 expression, indicating a potentially low on-target/off-tumor toxicity effect. Collectively, our data support the further evaluation for clinical assessment of CD28/4-1BB CD123 CAR T cells in BPDCN neoplasm.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bôle-Richard E, Fredon M, Biichlé S, et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2020. PMID: 32111969. doi:10.1038/s41375-020-0777-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。